NEW YORK, Sept. 08, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Vitamin Shoppe, Inc. ("Vitamin Shoppe") (NYSE:VSI) securities between March 1, 2017 and August 8, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/vitamin-shoppe-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) the Company's retail segment was continuing to dramatically decline, as its ongoing "reinvention plan" was not meeting with success; (2) ongoing changes to the Company's operating plan brought about through this "reinvention plan" had already rendered the more than $168 million in goodwill being carried on Vitamin Shoppe's books for the retail segment impaired and Vitamin Shoppe was improperly delaying recognizing that impairment charge; and (3) as a result of the foregoing, defendants lacked a reasonable basis for their positive statements about Vitamin Shoppe's financial prospects.
If you suffered a loss in Vitamin Shoppe you have until October 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/vitamin-shoppe-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]


Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



